Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate

J Clin Exp Hematop. 2020;60(1):26-28. doi: 10.3960/jslrt.18031.
No abstract available

Keywords: Forodesine; Peripheral T-cell lymphoma (PTCL); Pralatrexate (PDX); Relapse/Refractory; Retreatment.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aminopterin / analogs & derivatives*
  • Aminopterin / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Female
  • Humans
  • Lymph Nodes / drug effects
  • Lymph Nodes / pathology
  • Lymphoma, T-Cell, Peripheral / drug therapy*
  • Lymphoma, T-Cell, Peripheral / pathology
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / pathology
  • Prednisone / therapeutic use
  • Purine Nucleosides / therapeutic use*
  • Pyrimidinones / therapeutic use*
  • T-Lymphocytes, Helper-Inducer / drug effects
  • T-Lymphocytes, Helper-Inducer / pathology
  • Vincristine / therapeutic use

Substances

  • 10-propargyl-10-deazaaminopterin
  • Antineoplastic Agents
  • Purine Nucleosides
  • Pyrimidinones
  • forodesine
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Aminopterin
  • Prednisone

Supplementary concepts

  • CHOP protocol
  • COP protocol 2